CpG immunomer DNA enhances antisense protein kinase A RIα inhibition of multidrug-resistant colon carcinoma growth in nude mice: Molecular basis for combinatorial therapy

Clinical Cancer Research

Volumn 11, Issue 16, 2005, Pages 5950-5955

  Nesterova, Maria V ^a   Johnson, Natalie R ^a   Stewart, Trina ^a   Abrams, Scott ^a   Cho Chung, Yoon S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 6; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL ACTIVATION; CELL DIFFERENTIATION; COLON CARCINOMA; CONTROLLED STUDY; CPG ISLAND; ENZYME SUBUNIT; GENETIC TRANSCRIPTION; MOUSE; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPLEEN SIZE; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CPG ISLANDS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERLEUKIN-6; MICE; MICE, NUDE; NF-KAPPA B; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 23844526193     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0624     Document Type: Article

References (45)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
2. Hersh EM, Gutterman JU, Mavligit GM. BCG as adjuvant immunotherapy for neoplasia. Annu Rev Med 1977;28:489-515.
3. Bohle A, Brandau S. Immune mechanisms in Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003;170:964-9.
4. Tokunaga T, Yamamoto H, Shimada, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984;72:955-62.
5. Yamamoto S, Yamamoto T, Nojima Y, et al. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development. Jpn J Infect Dis 2002;55:37-44.
6. Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 1991;147:1759-64.
7. Krieg AM, Yi AK, Maison S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9.
8. Bird AP. CpG islands as gene markers in the vertebrate nucleus. Trends Genet 1987;3:342-7.
9. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J Immunol 2001;166:2372-7.
10. Krug A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur J Immunol 2001;31:2154-63.
11. Yu D, Kandimalla ER, Bhagat L, et al. 'Immunomers': novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res 2002;30:4460-9.
12. Kandimalla ER, Bhagat L, Wang D, et al. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res 2003;31:2393-400.
13. Kandimalla ER, Yu D, Zhao Q, Agrawal S. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure- immunostimulatory activity relationships. Bioorg Med Chem 2001;9:807-13.
14. Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int J Oncol 2004;24:901-8.
15. Zamecnik P, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 1978;75:280-4.
16. Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res 1990;50:7093-100.
17. Tortora G, Pepe S, Bianco C, et al. The RIα subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene 1994;9:3233-40.
18. Tortora G, Damiano V, Bianco C, et al. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene 1997;14:923-8.
19. Miller WR, Watson DM, Jack W, Chetty U, Elton RA. Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res Treat 1993;26:89-94.
20. Cho-Chung YS, Clair T, Tagliaferri P, et al. Site-selective cyclic AMP analogs as new biological tools in growth control, differentiation, and proto-oncogene regulation. Cancer Invest 1989;7:161-77.
21. Tortora G, Yokozaki H, Pepe S, Clair T, Cho-Chung YS. Differentiation of HL-60 leukemia cells by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 1991;88:2011-5.
22. Yokozaki H, Budillon A, Tortora G, et al. An antisense oligodeoxynucleotide that depletes RI α subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res 1993;53:868-72.
23. Nesterova M, Cho-Chung YS. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nat Med 1995;1:528-33.
24. Nesterova M, Cho-Chung YS. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIα subunit. Antisense Nucleic Acid Drug Dev 2000;10:423-33.
25. Srivastava RK, Srivastava AR, Seth P, Agrawal S, Cho-Chung YS. Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RI α subunit: p53-independent mechanism of action. Mol Cell Biochem 1999;195:25-36.
26. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 1998;18:3509-17.
27. Agrawal S, Jiang Z, Zhao Q, et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci U S A 1997;94:2620-5.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
29. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
30. Fried M, Crothers DM. Equilibria and kinetics of lac repressor-operator interactions by polyacrylamide gel electrophoresis. Nucleic Acids Res 1981;9:6505-25.
31. Zhao Q, Temsamani J, Zhou RZ, Agrawal S. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev 1997;7:495-502.
32. Branda RF, Moore AL, Mathews L, McCormack JJ, Zon G. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol 1993;45:2037-43.
33. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996;157:2116-22.
34. Ciardiello F, Tortora G. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin Cancer Res 1998;4:821-8.
35. Cho-Chung YS, Nesterova M, Kondrashin A, Noguchi K, Srivastava R, Pepe S. Antisense-protein kinase A: a single-gene-based therapeutic approach. Antisense Nucleic Acid Drug Dev 1997;7:217-23.
36. Nesterova M, Noguchi K, Park YG, Lee YN, Cho-Chung YS. Compensatory stabilization of RIIβ protein, cell cycle deregulation and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIα protein. Clin Cancer Res 2000;6:3434-41.
37. Alper O, Hacker NF, Cho-Chung YS. Protein kinase A-RIα subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway. Oncogene 1999;18:4999-5004.
38. Cho YS, Kim M-K, Tan R, Srivastava S, Agrawal S, Cho-Chung YS. Protein kinase A RIα antisense inhibition of prostate cancer growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation. Clin Cancer Res 2002;8:607-14.
39. Cho YS, Kim MK, Cheadle C, Neary C, Becker KG, Cho-Chung YS. Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc Natl Acad Sci U S A 2001;98:9819-23.
40. Srivastava RK, Srivastava AR, Park YG, Agrawal S, Cho-Chung YS. Antisense depletion of RIα subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells. Breast Cancer Res Treat 1998;49:97-107.
41. Tokunaga T, Yano O, Kuramoto E, et al. Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol 1992;36:55-66.
42. Scheule RK. The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev 2000;44:119-34.
43. Pisetzky DS. Mechanisms of immune stimulation by bacterial DNA. Springer Semin Immunopathol 2000;22:21-33.
44. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5.
45. Van Herreweghe F, Mao J, Chaplen FW, et al. Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE. Proc Natl Acad Sci U S A 2002;99:949-54.